Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | XDH | P47989 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27176959 | 0.90 | POLB (0.56) | KDM4EPOLBGAAL3MBTL1LMNA | |
| SCHEMBL25320756 | 0.90 | KMT2A (0.45) | KDM4EPOLBGAAL3MBTL1LMNA | |
| SCHEMBL27362105 | 0.90 | KDM4E (0.45) | KDM4EPOLBGAAL3MBTL1LMNA | |
| SCHEMBL31463421 | 0.90 | POLB (0.56) | KDM4EPOLBGAAL3MBTL1LMNA | |
| SCHEMBL26831170 | 0.89 | ALDH1A1 (0.44) | KDM4EPOLBGAAL3MBTL1LMNA | |
| SCHEMBL31123060 | 0.89 | NOTUM (0.43) | KDM4EPOLBGAAL3MBTL1LMNA | |
| SCHEMBL26970977 | 0.89 | POLB (0.42) | KDM4EPOLBGAAL3MBTL1LMNA | |
| SCHEMBL30269307 | 0.89 | POLB (0.44) | KDM4EPOLBGAAL3MBTL1LMNA | |
| SCHEMBL3646690 | 0.89 | NOTUM (0.43) | KDM4EPOLBGAAL3MBTL1LMNA | |
| SCHEMBL29159760 | 0.89 | POLB (0.44) | KDM4EPOLBGAAL3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748839-A1 | POLYCYCLIC COMPOUND AND USE THEREOF | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2026-05-27 | — | — | EP | disclosed |
| EP-4271674-B9 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12570642-B2 | GLP-IR modulating compounds | GILEAD SCIENCES, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260062416-A1 | INHIBITORS OF KIF18A AND USES THEREOF | ACCENT THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4688751-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | Enanta Pharmaceuticals, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4688144-A1 | COMPOUNDS AS GLP-1R AGONISTS | Terns Pharmaceuticals, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4691554-A2 | GLP-1R MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12497382-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250368659-A1 | Antiviral Heterocyclic Compounds | ENANTA PHARM INC (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4271672-B1 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-12-03 | — | — | EP | disclosed |
| CN-114630823-A | GLP-1R modulating compounds | 吉利德科学公司 | 2022-06-14 | — | — | CN | disclosed |
| US-20210171499-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2021-06-10 | — | — | US | disclosed |
| WO-2021081207-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| US-8093406-B2 | Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors | NOVARTIS AG (CH) | 2012-01-10 | — | — | US | disclosed |
| EP-2303857-A1 | CYCLIC SULFONES WITH AMINOBENZYL SUBSTITUTION USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| EP-2190833-A1 | AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS | Novartis Ag (CH) | 2010-06-02 | — | — | EP | disclosed |
| US-20100056490-A1 | Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
| WO-2010003976-A1 | CYCLIC SULFONES WITH AMINOBENZYL SUBSTITUTION USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2010-01-14 | — | — | WO | disclosed |
| WO-2009024615-A1 | AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2009-02-26 | — | — | WO | disclosed |
| US-20090054427-A1 | AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS | BRIARD EMMANUELLE | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054427-A1 | AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS | BACE2, BACE1, APP | KDM4E 1305/4885POLB 591/4885GAA 32/4885 |
| US-20100056490-A1 | Cyclic sulfones with aminobenzyl substitution useful as BACE inhibitors | BACE2, BACE1, APP | KDM4E 1167/4885POLB 549/4885GAA 35/4885 |
| US-20260062416-A1 | INHIBITORS OF KIF18A AND USES THEREOF | KIF18A, KIF18B, KIF5B | KDM4E 3550/4885POLB 151/4885GAA 2817/4885 |
| US-12570642-B2 | GLP-IR modulating compounds | GLP1R, GIPR, GPR119 | KDM4E 2438/4885POLB 4845/4885GAA 2636/4885 |
| US-20210171499-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | KDM4E 2322/4885POLB 4668/4885GAA 1038/4885 |
| US-20250368659-A1 | Antiviral Heterocyclic Compounds | ACE, HPRT1, ACE2 | KDM4E 1580/4885POLB 2792/4885GAA 1437/4885 |
| US-12497382-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | KDM4E 2322/4885POLB 4668/4885GAA 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.